



Form PTO-1449 (modified)

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Atty. Docket No.

UTXC:561USC1

Serial No.

10/673,671

Applicant

K. Jagannadha Sastry *et al.*

Filing Date:

September 29, 2003

Group:

1648

Unknown

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 2

Other Art

See Page 2

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
JS	A1	3,791,932	2/12/74	Schuurs <i>et al.</i>	195	103.5R	1/27/72
	A2	3,949,064	4/6/76	Bornstein <i>et al.</i>	424	1	10/26/73
	A3	4,174,384	11/13/79	Ullman <i>et al.</i>	424	8	10/12/76
	A4	4,367,110	1/4/83	Yoshikawa	156	219	6/27/80
	A5	4,452,901	6/5/84	Gordon <i>et al.</i>	436	506	3/18/80
	A6	4,554,101	11/19/85	Hopp	260	112.5R	1/28/83
	A7	4,578,770	3/25/86	Mitani	364	571	6/10/83
	A8	4,596,792	6/24/86	Vyas	514	21	3/30/84
	A9	4,599,230	7/8/86	Milich <i>et al.</i>	424	89	3/9/84
	A10	4,601,903	7/22/86	Frasch	424	92	5/1/85
	A11	4,608,251	8/26/86	Mia	424	85	11/9/84
	A12	4,683,195	7/28/87	Mullis <i>et al.</i>	435	6	2/7/86
	A13	4,683,202	11/27/90	Mullis	435	91	10/25/85
	A14	4,690,915	9/1/87	Rosenburg	514	2	8/8/85
	A15	4,797,368	1/10/89	Carter <i>et al.</i>	435	320	3/15/85
	A16	4,800,159	1/24/89	Mullis <i>et al.</i>	435	172.3	12/17/86
	A17	4,883,750	11/28/89	Whiteley <i>et al.</i>	435	6	12/13/84
	A18	4,942,628	7/24/90	Rosen <i>et al.</i>	530	326	6/13/88
	A19	5,028,592	7/2/91	Lipton	514	18	8/5/88
	A20	5,128,319	7/7/92	Arlinghaus	514	12	9/20/89
	A21	5,139,941	8/18/92	Muzyczka <i>et al.</i>	435	172.3	10/25/91
	A22	5,142,025	8/25/92	Putney <i>et al.</i>	530	350	9/24/90

EXAMINER:

/Jeffrey Stucker/

DATE CONSIDERED:

06/15/2006

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)

Atty. Docket No.

Serial No.

UTXC:561USC1

10/673,671

List of Patents and Publications for Applicant's

Applicant

K. Jagannadha Sastry *et al.*

INFORMATION DISCLOSURE STATEMENT

Filing Date:

Group:

September 29, 2003

Unknown

(Use several sheets if necessary)

U.S. Patent Documents

Foreign Patent Documents

Other Art

See Page 1

See Page 2

See Page 2

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
JS	A23	5,199,942	4/6/93	Gillis	604	4	9/26/91
	A24	5,221,605	6/22/93	Bard <i>et al.</i>	435	4	10/30/90
	A25	5,238,808	8/24/93	Bard <i>et al.</i>	435	4	10/24/85
	A26	5,279,721	1/18/94	Schmid	204	182.8	4/22/93
	A27	5,310,687	5/10/94	Bard <i>et al.</i>	436	518	11/4/91
	A28	5,620,896	4/15/97	Herrmann <i>et al.</i>	435	320.1	4/20/95
	A29	5,780,036	7/14/98	Chisari	424	189.1	4/4/95
	A30	5,958,895	9/28/99	Pachuk <i>et al.</i>	514	44	10/23/97
	A31	6,210,873	4/3/01	Sastry <i>et al.</i>	435	5	12/2/91
	A32	6,271,198	8-7-01	Braisted <i>et al.</i>	514	2	5-5-97

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
JS	B1	320308	6/14/89	Europe			
	B2	329822	8/30/89	Europe			
	B3	2202328	9/21/88	Great Britain			
	B4	WO 88/10315	12/29/88	PCT			
	B5	WO 89/06700	7/27/89	PCT			
	B6	WO 90/07641	7/12/90	PCT			
	B7	WO 93/10816	6/10/93	PCT			
	B8	WO 93/19775	10/14/93	PCT			
	B9	WO 96/33734	10/31/96	PCT			

EXAMINER: /Jeffrey Stucker/

DATE CONSIDERED: 06/15/2006

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)



Form PTO-1449 (modified)

Atty. Docket No.

UTXC:561USC1

Serial No.

10/673,671

Office of Patents and Publications for Applicant's

Applicant

K. Jagannadha Sastry *et al.*

INFORMATION DISCLOSURE STATEMENT

Filing Date:

September 29, 2003

Group:

Unknown

(Use several sheets if necessary)

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 2

Other Art

See Page 2

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
JS	B10	0 267 802	5/18/88	Europe	X	X	
	B11	0 273 716	7/6/88	Europe			
	B12	0 284 587	9/28/88	Europe			
	B13	WO 89/03844	5/5/89	PCT			
	B14	WO 89/07112	8/10/89	PCT			
	B15	WO 93/10816	6/10/93	PCT			

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
JS	C1	Agren <i>et al.</i> , "Genetically engineered nontoxic vaccine adjuvant that combines B cell targeting with immunomodulation by cholera toxin A1 subunit," <i>J. Immunol.</i> 158:3936-3946, 1997.
	C2	Aichele <i>et al.</i> , "Antiviral cytotoxic T cell response induced by in vivo priming with a free synthetic peptide," <i>J. Exp. Med.</i> , 171:1815-1820, 1990.
	C3	Altman <i>et al.</i> , "Phenotypic analysis of antigen-specific T lymphocytes," <i>Science</i> , 274:94-96, 1996.
	C4	An and Whitton, "A multivalent minigene vaccine, containing B-cell, cytotoxic T-lymphocyte, and T _H epitopes from several microbes, induces appropriate responses in vivo and confers protection against more than one pathogen," <i>J. Virol.</i> , 71(3):2292-2302, 1997.
	C5	Barry <i>et al.</i> , "Protection against mycoplasma infection using expression-library immunization," <i>Nature</i> , 377:632-635, 1995.
	C6	Berzofsky, "Development of artificial vaccines against HIV using defined epitopes," <i>FASEB J.</i> , 5:2412-2418, 1991.
	C7	Bevan, "Stimulating killer cells," <i>Nature</i> , 342:478-479, 1989.
	C8	Bogedain <i>et al.</i> , "Specific cytotoxic T lymphocytes recognize the immediate-early transactivator ZTA of Epstein-Barr virus," <i>J. Virol.</i> , 69(8):4872-4879, 1995.

EXAMINER: /Jeffrey Stucker/

DATE CONSIDERED: 06/15/2006

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)

Atty. D cket No.

Serial No.

UTXC:561USC1

10/673,671

List of Patents and Publications for Applicant's

Applicant

K. Jagannadha Sastry *et al.*

INFORMATION DISCLOSURE STATEMENT

Filing Date:

September 29, 2003

Group:

Unknown

(Use several sheets if necessary)

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 2

Other Art

See Page 2

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
JS	C9	Boyson <i>et al.</i> , The MHC class I genes of the rhesus monkey," <i>J. Immunol.</i> 156:4656-4665, 1996.
	C10	Braciale <i>et al.</i> , "Antigen presentation pathways to class I and class II MHC-restricted T lymphocytes," <i>Immunol. Rev.</i> , 98:95-114, 1987.
	C11	Carmichael <i>et al.</i> , "Quantitative analysis of the human immunodeficiency virus Type I (HIV-1)-specific cytotoxic T lymphocyte (CTL) response at different stages of HIV-1 infection: differential CTL responses to HIV-1 and Epstein-Barr virus in late disease," <i>J. Exp. Med.</i> , 177:249-256, 1993.
	C12	Casement <i>et al.</i> , "Cross-reactive cytotoxic T lymphocytes induced by V3 loop synthetic peptides from different strains of human immunodeficiency virus type I," <i>Virology</i> , 211(1):261-67, 1995.
	C13	Chopra <i>et al.</i> , "Cloning and expression of putative cytotoxic enterotoxin-encoding genes from <i>Aeromonas hydrophila</i> ," <i>Gene</i> 139:87-91, 1994.
	C14	Chopra <i>et al.</i> , Molecular and biochemical characterization of a heat-labile cytotoxic enterotoxin from <i>Aeromonas hydrophila</i> ," <i>Microbial Path.</i> 21:357-377, 1996.
	C15	Ciernik <i>et al.</i> , "Induction of cytotoxic T lymphocytes and antitumor immunity with DNA vaccines expressing single T cell epitopes," <i>J. Immunol.</i> , 156:2369-2375, 1996.
	C16	Clerget-Raslain <i>et al.</i> , "Specificity of anti-peptide antibodies elicited against synthetic peptides mimicking conserved regions of HIV1 envelope glycoprotein," <i>Res. Virol.</i> , 142:423-438, 1991.
	C17	Dadaglio <i>et al.</i> , "Epitope recognition of conserved HIV envelope sequences by human cytotoxic T lymphocytes," <i>J. Immunol.</i> , 147:2302-2309, 1991.
	C18	Dai <i>et al.</i> , "Mutation of human immunodeficiency virus type 1 at amino acid 585 on gp41 results in loss of killing by CD8 ⁺ A24-restricted cytotoxic T lymphocytes," <i>J. Virol.</i> , 66:3151-3154, 1992.
	C19	De Rossi <i>et al.</i> , "Synthetic peptides from the principal neutralizing domain of human immunodeficiency virus type 1 (HIV-1) enhance HIV-1 infection through a CD4-dependent mechanism," <i>Virology</i> , 184:187-196, 1991.

EXAMINER:

/Jeffrey Stucker/

DATE CONSIDERED:

06/15/2006

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)



Form PTO-1449 (modified)

Atty. Docket No.
UTXC:561USC1Serial No.
10/673,671

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

Applicant
K. Jagannadha Sastry *et al.*

(Use several sheets if necessary)

Filing Date:
September 29, 2003Group:
UnknownU.S. Patent Documents
See Page 1Foreign Patent Documents
See Page 2Other Art
See Page 2

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
JS	C20	Del Guercio <i>et al.</i> , "Potent immunogenic short linear peptide constructs composed of B cell epitopes and Pan DR T helper epitopes (PADRE) for antibody responses <i>in vivo</i> ," Vaccine 15:441-448, 1997.
	C21	Deres <i>et al.</i> , "In vivo priming of virus specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine," Nature, 342:561-564, 1989.
	C22	Dupuis <i>et al.</i> , "Characterization of HLA-A*0201-restricted cytotoxic T cell epitopes in conserved regions of the HIV type 1 gp160 protein," J. Immunol., 155:2232-2239, 1995.
	C23	Falk <i>et al.</i> , "Allele-specific peptide ligand motifs of HLA-C molecules," Proc. Nat'l Acad. Sci. USA, 90:12005-12009, 1993.
	C24	Falk <i>et al.</i>, "Allele-specific peptide ligand motifs of HLA-C molecules," Proc. Nat'l Acad. Sci. USA, 90:12005-12009, 1993. Duplicate of C23
JS	C25	Falk <i>et al.</i> , "Expression of HLA-C molecules confers target cell resistance to some non-major histocompatibility complex-restricted T cells in a manner analogous to allospecific natural killer cells," J. Exp. Med., 182:1005-1018, 1995.
	C26	Ferguson <i>et al.</i> , "Amino-acid residues involved in biological functions of the cytolytic enterotoxin from <i>Aeromonas hydrophila</i> ," Gene 156:79-83, 1995.
	C27	Ferguson <i>et al.</i> , "Hyperproduction, purification, and mechanism of action of the cytotoxic enterotoxin produced by <i>Aeromonas hydrophila</i> ," Infect. Immun. 65:4299-4308, 1997.
	C28	Flotte <i>et al.</i> , "An improved system for packaging recombinant adeno-associated virus vectors capable of in vivo transduction," Gene Therapy, 2:29-37, 1995.
	C29	Fuller and Haynes, "A qualitative progression in HIV type 1 glycoprotein 120-specific cytotoxic cellular and humoral immune responses in mice receiving a DNA-based glycoprotein 120 vaccine," AIDS Res. Hum. Retroviruses, 11:1433-1441, 1994.
	C30	Gallichan and Rosenthal, "Long-lived cytotoxic T lymphocyte memory in mucosal tissues after mucosal but not systemic immunization," J. Exp. Med. 181:1879-1890, 1996.
	C31	Gao <i>et al.</i> , "Priming of influenza virus-specific cytotoxic T lymphocytes <i>vivo</i> by short synthetic peptides," J. Immun., 147(10):3268-3273.

EXAMINER: /Jeffrey Stucker/

DATE CONSIDERED: 06/15/2006

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)



Form PTO-1449 (modified)		Atty. Docket No. UTXC:561USC1	Serial No. 10/673,671
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant K. Jagannadha Sastry <i>et al.</i>	
		Filing Date: September 29, 2003	Group: Unknown
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Page 2</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
JS	C32	Gorse <i>et al.</i> , "Recombinant gp160 vaccination schedule and MHC HLA type as factors influencing cellular responses to HIV-1 envelope glycoprotein," <i>Vaccine</i> , 13(13):1170-1179, 1995.
	C33	Goulder <i>et al.</i> , "Novel, cross-restricted, conserved and immunodominant cytotoxic T lymphocyte epitopes in slow progressors in HIV type I infection," <i>AIDS Res. Hum. Retroviruses</i> , 12(18):1691-1698, 1996.
	C34	Gussow <i>et al.</i> , "Isolation, expression and the primary structure of <i>HLA-Cw1</i> and <i>HLA-Cw2</i> genes: evolutionary aspects," <i>Immunogenetics</i> , 25:313-322, 1987.
	C35	Imaoka <i>et al.</i> , "Nasal immunization of nonhuman primates with simian immunodeficiency virus p55 ^{gag} and cholera toxin adjuvant induces Th1/Th2 help for virus specific immune responses in reproductive tissues," <i>J. Immunol.</i> , 161:5952-5958, 1998.
	C36	Ishioka <i>et al.</i> , "Utilization of MHC class I transgenic mice for development of minigene DNA vaccines encoding multiple HLA-restricted CTL epitopes," <i>J. Immunol.</i> , 162:3915-3925, 1999.
	C37	Jassey <i>et al.</i> , "Detection of a vigorous HIV-1-specific cytotoxic T lymphocyte response in cerebrospinal fluid from infected persons with AIDS dementia complex," <i>J. Immunol.</i> , 149:3113-3119, 1992.
	C38	Johnson <i>et al.</i> , "Identification of overlapping HLA class I-restricted cytotoxic epitopes in a conserved region of the human immunodeficiency virus type 1 envelope glycoprotein: definition of minimum epitopes and analysis of the effects of sequence variation," <i>J. Exp. Med.</i> , 175:961-971, 1992.
	C39	Johnson <i>et al.</i> , "Recognition of a highly conserved region of human immunodeficiency virus type 1 gp120 by an HLA-Cw4-restricted cytotoxic T-lymphocyte clone," <i>J. Virol.</i> , 67(1):438-445, 1993.
	C40	Kast <i>et al.</i> , "Protection against lethal Sendai virus infection by <i>in vivo</i> priming of virus-specific cytotoxic T lymphocytes with a free synthetic peptide," <i>Proc. Nat'l Acad. Sci. USA</i> , 88:2283, 1991.
	C41	Keusch <i>et al.</i> , "Classification of enterotoxins on the basis of activity in cell culture," <i>J. Infect. Dis.</i> 131(1):58-63, 1973.

EXAMINER: /Jeffrey Stucker/

DATE CONSIDERED: 06/15/2006

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)



Form PTO-1449 (modified)

Atty. Docket No.

UTXC:561USC1

Serial No.

10/673,671

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Applicant

K. Jagannadha Sastry *et al.*

Filing Date:

September 29, 2003

Group:

Unknown

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 2

Other Art

See Page 2

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
JS	C42	Klein <i>et al.</i> , "Kinetics of gag-specific cytotoxic T-lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics," <i>J. Exp. Med.</i> , 181:1365-1372, 1995.
	C43	Koup <i>et al.</i> , "Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome," <i>J. Virol.</i> , 68:4650-4655, 1994.
	C44	Levy, "Pathogenesis of HIV infection," <i>Microbiol. Rev.</i> , 57:185-253, 1993.
	C45	Littaua <i>et al.</i> , "An HLA-C-restricted CD8+ cytotoxic T-Lymphocyte clone recognizes a highly conserved epitope on human immunodeficiency virus type 1 gag," <i>J. Virol.</i> , 65:4051-4056, 1991.
	C46	Lu <i>et al.</i> , "Use of DNAs expressing HIV-1 Env and noninfectious HIV-1 particles to raise antibody responses in mice," <i>Virology</i> , 209:147-154, 1995.
	C47	Merino <i>et al.</i> , "Emerging Pathogens: <i>Aeromonas</i> spp.," <i>Int'l. J. Food. Microbiol.</i> 28:157-168, 1995.
	C48	Modrow <i>et al.</i> , "Computer-assisted analysis of envelope protein sequences of seven human immunodeficiency virus isolates: prediction of antigenic epitopes in conserved and variable regions," <i>J. Virol.</i> 61:570-578, 1987.
	C49	Mortara <i>et al.</i> , "Type 1 CD4 ⁺ T-cell help is required for induction of antipeptide multispecific cytotoxic T lymphocytes by a lipopeptidic vaccine in rhesus macaques," <i>J. Virol.</i> 73:4447-4451, 1999.
	C50	Musey <i>et al.</i> , "Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection," <i>New Engl. J. Med.</i> , 337(18):1267-1274, 1997.
	C51	Muzyczka, "Use of adeno-associated virus as a general transduction vector for mammalian cells," <i>Curr. Top. Microbiol. Immunol.</i> , 158:97-129, 1992.
	C52	Nehete <i>et al.</i> , "A synthetic peptide from the first conserved region in the envelope protein gp160 is a strong T-cell epitope in HIV-infected chimpanzees and humans," <i>Vir. Immunol.</i> , 11(3):147-158, 1998.

EXAMINER: /Jeffrey Stucker/

DATE CONSIDERED: 06/15/2006

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)



Form PTO-1449 (modified)		Atty. Docket No. UTXC:561USC1	Serial No. 10/673,671
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant K. Jagannadha Sastry <i>et al.</i>	
		Filing Date: September 29, 2003	Group: Unknown
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Page 2</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
JS	C53	Nehete <i>et al.</i> , "Cross-reactive T-cell proliferative responses to V3 peptides corresponding to different geographical HIV-1 isolates in HIV-seropositive individuals," <i>J. Clin. Immunol.</i> , 16(2):115-124, 1996.
	C54	Nehete <i>et al.</i> , "Induction of human immunodeficiency virus-specific T cell responses in rhesus monkeys by synthetic peptides from gp160," <i>AIDS Res. Hum. Retroviruses</i> , 9:235-240, 1993.
	C55	Nehete <i>et al.</i> , "Presence of HLA-C-restricted cytotoxic T-lymphocyte responses in long-term nonprogressors infected with human immunodeficiency virus," <i>Vir. Immunol.</i> , 11(3):119-129, 1998.
	C56	Nehete <i>et al.</i> , "Studies on <i>in vivo</i> induction of HIV-1 envelope-specific cytotoxic T lymphocytes by synthetic peptides from V3 loop region of HIV-1 IIIB gp120," <i>Cell. Immunol.</i> , 160:217, 1995.
	C57	Nehete <i>et al.</i> , "Studies on V3-specific cross-reactive T-cell responses in chimpanzees chronically infected with HIV-1 _{IIIB} ," <i>AIDS</i> 9:567-572, 1995.
	C58	Nehete <i>et al.</i> , "Use of helper T cell-inducing peptides from conserved regions in HIV-1 <i>env</i> in a noncovalent mixture with a CTL-inducing V3-loop peptide for <i>in vivo</i> induction of long-lasting systemic CTL response," <i>Vir. Immunol.</i> , 7(4):189-197, 1994.
	C59	Pantaleo <i>et al.</i> , "Major expansion of CD8 ⁺ T cells with a predominant V β usage during the primary immune response to HIV," <i>Nature</i> , 370:463-467, 1994.
	C60	Peterson <i>et al.</i> , "Cholera toxin B subunit activates arachidonic acid metabolism," <i>Infect. Immunol.</i> 67:794-799, 1999.
	C61	Picard <i>et al.</i> , "A 2-year follow-up of an anti-HIV immune reaction in HIV-1 gp160-immunized healthy seronegative humans: evidence for persistent cell-mediated immunity," <i>J. Acquired Immune Defic. Syndr.</i> , 5:539-546, 1992.
	C62	Pontesilli <i>et al.</i> , "HIV-specific lymphoproliferative responses in asymptomatic HIV-infected individuals," <i>Clin. Exp. Immunol.</i> , 100:419-424, 1995.
	C63	Porgador <i>et al.</i> , Intranasal immunization with CTL epitope peptides from HIV-1 or ovalbumin and the mucosal adjuvant cholera toxin induces peptide-specific CTLs and protection against tumor development <i>in vivo</i> ," <i>J. Immunol.</i> 158:834-841, 1997.

EXAMINER: /Jeffrey Stucker/	DATE CONSIDERED: 06/15/2006
-----------------------------	-----------------------------

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)



Form PTO-1449 (modified)	Atty. Docket No. UTXC:561USC1	Serial No. 10/673,671
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Applicant K. Jagannadha Sastry <i>et al.</i>	
	Filing Date: September 29, 2003	Group: Unknown
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Page 2</i>

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
JS	C64	Roos <i>et al.</i> , "T cell function in vitro is an independent progression marker for AIDS in human immunodeficiency virus-infected asymptomatic subjects," <i>J. Infect. Dis.</i> , 171:531-536, 1995.
	C65	Rosenberg <i>et al.</i> , <i>Science</i> , "Vigorous HIV-1-specific CD4 ⁺ T cell responses associated with control of viremia," 278:1447-1450, 1997.
	C66	Rowland-Jones <i>et al.</i> , "HIV-specific cytotoxic T-cell activity in an HIV-exposed but uninfected infant," <i>Lancet</i> , 341:860-861, 1993.
	C67	Rowland-Jones <i>et al.</i> , "HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women," <i>Nature Med.</i> , 1:59-64, 1995.
	C68	Sarkar <i>et al.</i> , "Studies on <i>in vivo</i> induction of cytotoxic T lymphocyte responses by synthetic peptides from E6 and E7 oncoproteins of human papillomavirus type 16," <i>Viral Imm.</i> , 8:165-174, 1995.
	C69	Sastry and Arlinghaus, "Identification of T-cell epitopes without B-cell activity in the first and second conserved regions of the HIV Env protein," <i>AIDS</i> , 5:699-707, 1991.
	C70	Sastry <i>et al.</i> , "Rapid <i>in vivo</i> induction of HIV-specific CD8 ⁺ cytotoxic T lymphocytes by a 15-amino acid unmodified free peptide from the immunodominant V3-loop of GP120," <i>Virology</i> , 188:502-509, 1992.
	C71	Schendel <i>et al.</i> , "Cytotoxic T lymphocytes show HLA-C-restricted recognition of EBV-bearing cells and allorecognition of HLA class I molecules presenting self-peptides," <i>J. Immunol.</i> , 149:2406-2416, 1992.
	C72	Schrier <i>et al.</i> , "T cell recognition of HIV synthetic peptides in a natural infection," <i>J. Immunol.</i> , 142:1166-1176.
	C73	Sedegah <i>et al.</i> , "Protection against malaria by immunization with plasmid DNA encoding circumsporozoite protein," <i>Immunology</i> , 91:9866-9870, 1994.
	C74	Takahashi <i>et al.</i> , Specific lysis of human immunodeficiency virus type 1-infected cells by a HLC-A3.1-restricted CD8 ⁺ cytotoxic T-lymphocyte clone that recognizes a conserved peptide sequence within the gp41 subunit of the envelope protein," <i>Proc. Natl. Acad. Sci. USA</i> , 88:10277-10281, 1991.

EXAMINER: /Jeffrey Stucker/	DATE CONSIDERED: 06/15/2006
-----------------------------	-----------------------------

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)

Atty. Docket No.

UTXC:561USC1

Serial No.

10/673,671

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Applicant

K. Jagannadha Sastry *et al.*

Filing Date:

September 29, 2003

Group:

Unknown

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 2

Other Art

See Page 2

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
JS	C75	Ulmer <i>et al.</i> , "Heterologous protection against influenza by injection of DNA encoding a viral protein," <i>Science</i> , 259:1745-1749, 1993.
	C76	Unanue & Cerottini, "Antigen presentation," <i>FASEB J.</i> 3:2496-2502, 1989.
	C77	van den Eynde <i>et al.</i> , "A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma," <i>J. Exp. Med.</i> , 182:689-698, 1995.
	C78	Wang <i>et al.</i> , "Simultaneous induction of multiple antigen-specific cytotoxic T lymphocytes in nonhuman primates by immunization with a mixture of four <i>plasmodium falciparum</i> DNA plasmids," <i>Infect. Imm.</i> , 66(9):4193-4202, 1998.
	C79	Xiang <i>et al.</i> , "Vaccination with a plasmid vector carrying the rabies virus glycoprotein gene induces protective immunity against rabies virus," <i>Virology</i> , 199:132-140, 1994.
	C80	Xu <i>et al.</i> , "Role of a cytotoxic enterotoxin in <i>Aeromonas</i> -mediated infections: development of transposon and isogenic mutants," <i>Infect. Immun.</i> 66:3501-3509, 1998.
	C81	Yamada <i>et al.</i> , "Incidence and clinical symptoms of <i>Aeromonas</i> -associated travellers' diarrhoea in Tokyo," <i>Epidemiol. & Infect.</i> 119:121-126, 1997.
	C82	Yasutomi <i>et al.</i> , "Simian immunodeficiency virus-specific cytotoxic T-lymphocyte induction through DNA vaccination of rhesus monkeys," <i>J. Virol.</i> , 70:678-681, 1996.
	C83	Yokoyama <i>et al.</i> , "DNA immunization confers protection against lethal lymphocytic choriomeningitis virus infection," <i>J. Virol.</i> , 69(4):2684-2688, 1995.
	C84	Zemmour and Parham, "HLA class I nucleotide sequences, 1992," <i>Immunogenetics</i> , 37:239-250, 1993.

EXAMINER: /Jeffrey Stucker/

DATE CONSIDERED: 06/15/2006

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)